Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.72B P/E 118.99 EPS this Y 11.70% Ern Qtrly Grth -
Income 974M Forward P/E 26.66 EPS next Y 14.10% 50D Avg Chg 1.00%
Sales 9.45B PEG 1.62 EPS past 5Y 9.19% 200D Avg Chg 13.00%
Dividend N/A Price/Book 2.04 EPS next 5Y 15.91% 52W High Chg -5.00%
Recommedations 2.10 Quick Ratio 1.28 Shares Outstanding 493.24M 52W Low Chg 49.00%
Insider Own 0.14% ROA 2.17% Shares Float 492.28M Beta 0.67
Inst Own 65.83% ROE 4.83% Shares Shorted/Prior 3.33M/3.96M Price 82.10
Gross Margin 55.49% Profit Margin 10.30% Avg. Volume 777,345 Target Price 91.68
Oper. Margin 8.12% Earnings Date - Volume 669,333 Change -1.86%
About Alcon Inc.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alcon Inc. News
04/07/24 Alcon Publishes Agenda for 2024 Annual General Meeting
04/03/24 Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
04/03/24 Investing in Alcon (VTX:ALC) five years ago would have delivered you a 29% gain
08:50 AM Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
03/19/24 Here's Why We Think Alcon (VTX:ALC) Might Deserve Your Attention Today
03/13/24 Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership
03/12/24 Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India
03/08/24 Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone
03/06/24 Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
03/06/24 Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
02/29/24 Alcon Full Year 2023 Earnings: EPS Beats Expectations
02/29/24 Alcon Inc. (NYSE:ALC) Q4 2023 Earnings Call Transcript
02/29/24 20 Countries With Worst Vision Problems
02/28/24 Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand
02/28/24 Alcon Inc.'s (VTX:ALC) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
02/27/24 Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
02/27/24 Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
02/27/24 Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
02/22/24 Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings
02/01/24 Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopia
ALC Chatroom

User Image DonCorleone77 Posted - 2 weeks ago

$ALC Alcon initiated with a Buy at Goldman Sachs Goldman Sachs initiated coverage of Alcon with a Buy rating and $100 price target. Alcon's core businesses are delivering solid growth, supported by strong market positions and attractive end markets, the analyst tells investors in a research note. The firm also sees multiple opportunities for the company drive incremental growth. Alcon should sees share gains in contact lenses, driven by reusable contacts following launches in the TOTAL30 portfolio and pending launch of PRECISION7, contends Goldman.

User Image lawson Posted - 2 weeks ago

$ALC $SGHT patent infringement jury selection begins pretty soon between Alcon and sight sciences. We have a good sales and efficacy history with sight sciences’ products. Seems to me that the quickest fix for Alcon’s problems is to buy sight sciences, lock, stock, and barrel. Alcon gets two great products, whatever sight sciences has in development, and they make their legal problems go away, all at once.

User Image Stock_Titan Posted - 2 weeks ago

$ALC Alcon Publishes Agenda for 2024 Annual General Meeting https://www.stocktitan.net/news/ALC/alcon-publishes-agenda-for-2024-annual-general-a75n75tg044z.html

User Image Stock_Titan Posted - 1 month ago

$ALC Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India https://www.stocktitan.net/news/ALC/alcon-strengthens-leadership-in-iol-innovation-with-the-launch-of-30yrln3joi7j.html

User Image AnchorsAweigh Posted - 1 month ago

$ALC fat base

User Image Stock_Titan Posted - 1 month ago

$ALC Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone https://www.stocktitan.net/news/ALC/vivity-the-world-s-leading-edof-iol-reaches-one-million-i2b1th2n9zwo.html

User Image G101SPM Posted - 1 month ago

$ALC $85.38.... SELL/TAKE PROFIT ON BALANCE OF POSITION. DAC (dollar average cost) $77.91 .

User Image Broview Posted - 1 month ago

$ALC not cheap but with potential

User Image TickerDD_com Posted - 1 month ago

From 3/1/2024, looking back across 22 Month-Ends for ALC, Percentage Change of Average Monthly Price had More Positives (59%) while Percentage Change of Average Monthly Volume had More Positives (95%) $ALC #ALC #ALCStock #TickerDD #ALCPrice https://www.youtube.com/watch?v=bUD34V_VaJY

User Image satsandstocks Posted - 1 month ago

$ALC - Best kind of continuation

User Image G101SPM Posted - 1 month ago

$ALC $85.87. DAC $77.91 (2.20.24). EXIT $90.00 UPDATE: Piper Sandler analyst Anthony Petrone maintains Alcon(ALC) with a Buy and raises the price target from $95 to $100.

User Image G101SPM Posted - 02/29/24

$ALC $85.43 bid. SELL/TAKE PROFIT ON 1/2 OF LONG POSITION. RETAIN EXIT ($90.00) FOR REMAINING POSITION. DAC (dollar average cost) $77.91 (2.20.24).

User Image G101SPM Posted - 02/28/24

$ALC $85.64 +4.48. DAC (dollar average cost) $77.91 (2.20.24). CHANGE EXIT TO $90.00 FROM $88.00. UPDATE: Needham Raises Alcon's PT to $98 From $86 After 'Solid' Q4 2023 Results, Above-Consensus 2024 Guidance; Keeps Buy Rating

User Image xMonti Posted - 02/28/24

$ALC Alcon Non-GAAP EPS of $0.70 beats by $0.02, revenue of $2.33B misses by $10M

User Image G101SPM Posted - 02/28/24

$ALC $85.00 bid. DAC $77.91. CHANGE EXIT TO $88.00 FROM $84.00 on improved SPM tag. UPDATE: Needham analyst David Saxon reiterates Alcon(ALC) with a Buy and maintains $86 price target.

User Image Estimize Posted - 02/27/24

$ALC misses the Estimize EPS Consensus by 2c and the Estimize Revenue Consensus by $14.83M. Reports FQ4 earnings of 70c EPS and $2.33B ... http://www.estimize.com/alc/fq4-2023?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image G101SPM Posted - 02/27/24

$ALC $81.18 last bid. DAC $77.91 (2.20.24). EXIT $84.00. UPDATE: Q4 2023 sales of $2.3 billion, up 8%, or 10% constant currency; Q4 2023 diluted EPS of $0.86, compared to a loss in the prior year(3); core diluted EPS(2) of $0.70 up 67%, or 78%; FY 2023 sales of $9.4 billion, up 8%, or 10% ; FY 2023 diluted EPS of $1.96, up 188%; core diluted EPS of $2.74, up 22%, or 33%. ^FY 2024 outlook: 6% to 8% cc sales growth, 13% to 16% cc core diluted EPS growth OVERVIEW: Form 6-K ALCON INC For: Dec 31 http://archive.fast-edgar.com/20240227/A8ZZB22CZ222P2Z2222A22ZZBNDLZWQ83X62 ... Filed on: February 27, 2024

User Image epsguid Posted - 02/27/24

$ALC reported earnings of $0.70, consensus was $0.68 via @eWhispers #epsbeat http://eps.sh/d/alc

User Image DonCorleone77 Posted - 02/27/24

$ALC Alcon sees FY24 core EPS $3.00-$3.10, consensus $3.04 Sees FY24 revenue $9.9B-$10.1B, consensus $9.95B.

User Image DonCorleone77 Posted - 02/27/24

$ALC Alcon reports Q4 core EPS 70c, consensus 68c Reports Q4 revenue $2.3B, consensus $2.34B. David J. Endicott, Alcon's Chief Executive Officer, said, "2023 was an excellent year for Alcon, and I'm proud of what our team accomplished. We delivered solid top-line growth in both franchises on the back of healthy markets. We also grew earnings and expanded margins, all while successfully completing our transformation program and advancing our product pipeline."

User Image Stock_Titan Posted - 02/27/24

$ALC Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023 https://www.stocktitan.net/news/ALC/alcon-s-broad-portfolio-delivers-robust-sales-and-earnings-growth-in-3c2bs96rajaz.html

User Image thejuiceboxyears Posted - 2 months ago

$EYE $COO $ALC $GNOM $IBB I work with smart people. Look what they did… https://www.futurity.org/nanomaterial-retina-implant-restore-sight-3184152/

User Image StockInvest_us Posted - 2 months ago

Signal alert: $ALC - Double Top https://stockinvest.us/l/xXsppdEzz2

User Image G101SPM Posted - 2 months ago

$ALC $80.34 +0.58. DAC $77.91 (2.20.24) CHANGE EXIT TO $84.00 FROM $81.00 on improved SPM tag. EA2.27

User Image G101SPM Posted - 2 months ago

$ALC $77.97.... BUY/NEW LONG POSITION carries SPM 87. 24 tag as earnings trade to $81.00 EXIT. EA2.20

User Image digitalcori Posted - 2 months ago

💼 Discover the investment strategies of the pros! 📈AKO Capital LLP's Q4 2023 portfolio reveals the path to sustainable returns! #FinanceTips Valued at $7.03 Billion and featuring 29 different stocks. Top holding: $ALC, $V, $MSFT, $ACN, and $BKNG https://tickertracker.io/articles/e1djyx782r-ako-capital-llp-s-q4-2023-portfolio-a-strategic-approach-to-sustainable-returns

User Image xMonti Posted - 2 months ago

$RXST ATH 52week. Ready for taking major market share of cataract lens - $JNJ $ALC

User Image Thestocktraderhubzee Posted - 2 months ago

$ALC Keybanc Initiates Coverage On Alcon with Overweight Rating, Announces Price Target of $87

User Image xMonti Posted - 01/31/24

$ALC Hoya upset … https://news.bloomberglaw.com/ip-law/alcon-partially-beats-hoya-patent-suit-over-cataract-treatment

User Image xMonti Posted - 01/31/24

$ALC dump !! $53 .. Tough competition.. new emerging players - both drug and contacts lens under pressure. $JNJ $COO $GKOS $EYPT

Analyst Ratings
Stifel Buy Apr 22, 24
Goldman Sachs Buy Apr 10, 24
Stifel Buy Mar 13, 24
Argus Research Buy Mar 4, 24
Mizuho Buy Mar 1, 24
Keybanc Overweight Feb 29, 24
Bernstein Outperform Feb 29, 24
Needham Buy Feb 28, 24
Keybanc Overweight Feb 6, 24